Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension

The KARDIA-2 study met its primary endpoint demonstrating additive, placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHgat month three. These results were statistically significant and clinically meaningfulZilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives Basel, 7 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam today released detailed results from the Phase II KARDIA-2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care (SOC) antihypertensives. The data were presented as a late-breaking clinical trial at the 2024 American College of Cardiology (ACC) Annual Scientific Session and follow the positiveKARDIA-2 topline results announced in March 2024.The study achieved its primary endpoint showing statistically significant and clinically meaningful additive, placebo-adjusted systolic blood pressure (SBP) reductions of up to 12.1 mmHg at month three (assessed by 24-hour ambulatory blood pressure monitoring, ABPM) when adding zilebesiran to SOC antihypertensives including a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine) or angiotensin receptor blocker (olmesartan).In addition, the study met its key secondary endpoint evaluated at month three, with a single dose of zilebesiran demonstrating clinically significant additive reductions in office SBP across all three independent cohor...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news